Connectome-Based Growth Models Reveal Individual Heterogeneity and Neurophysiological Subtypes of Subthreshold Depression

Why It Matters

Identifying brain‑based subtypes enables early, personalized interventions for depression risk and guides selection of non‑pharmacologic therapies such as light therapy.

Key Takeaways

• Normative connectome modeling quantifies individual brain deviations in StD.
• Two StD subtypes show opposite functional connectivity patterns.
• Subtype 1 links to suicide risk and specific gene pathways.
• Bright‑light therapy benefits differ between subtypes, predicting response.
• Baseline connectome deviations forecast treatment outcome for subtype 1.

Pulse Analysis

Normative modeling of the functional connectome offers a powerful alternative to traditional case‑control designs, capturing the spectrum of individual brain alterations that underlie subthreshold depression. By training Gaussian‑process regression models on over a thousand healthy participants, researchers established age‑ and sex‑adjusted reference trajectories for functional connectivity strength across 220 cortical and subcortical parcels. Applying these models to StD patients highlighted extensive heterogeneity: most individuals deviated in unique regional patterns, underscoring the limitation of group‑averaged analyses and the need for personalized neuroimaging biomarkers.

Clustering of deviation maps identified two biologically distinct StD subtypes. Subtype 1 displayed heightened connectivity in the default‑mode, limbic, and subcortical circuits while showing reduced connectivity in sensorimotor and attentional networks, a profile that correlated with elevated suicide item scores and slower cognitive processing. Transcriptomic linkage using the Allen Human Brain Atlas revealed enrichment of genes governing synaptic assembly and calcium signaling, suggesting a deeper neurodevelopmental vulnerability. In contrast, Subtype 2 exhibited milder, opposite connectivity shifts and lacked a robust gene‑expression signature, indicating a potentially different etiological pathway. These findings align with emerging evidence that depressive disorders comprise multiple neurobiological phenotypes rather than a single homogeneous entity.

Therapeutically, the study demonstrated that an eight‑week bright‑light therapy regimen produced overall symptom relief, yet only Subtype 1 experienced significant reductions in suicidal ideation and normalization of prefrontal connectivity. Moreover, baseline deviation patterns successfully predicted treatment magnitude for Subtype 1, highlighting the promise of connectome‑based predictors in precision psychiatry. Future work should expand multimodal imaging, longitudinal tracking, and larger intervention cohorts to refine subtype definitions and translate these biomarkers into routine clinical decision‑making, ultimately improving outcomes for individuals at the earliest stages of depressive illness.